[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4013 Introduced in House (IH)]






108th CONGRESS
  2d Session
                                H. R. 4013

   To amend the Federal Food, Drug, and Cosmetic Act to prohibit the 
 approval of any drug that infringes the right to life, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             March 23, 2004

 Mr. Gingrey introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
   To amend the Federal Food, Drug, and Cosmetic Act to prohibit the 
 approval of any drug that infringes the right to life, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. FEDERAL FOOD, DRUG, AND COSMETIC ACT; PROHIBITION AGAINST 
              APPROVAL OF DRUG INFRINGING RIGHT TO LIFE.

    Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355) is amended by adding at the end the following subsection:
    ``(o)(1) Notwithstanding any other provision of this section, the 
Secretary may not approve an application under subsection (b) or (j) 
for a drug whose intended use would infringe the right to life. Drugs 
whose approval is prohibited under the preceding sentence include a 
drug intended to assist with the act of suicide and a drug intended to 
induce an abortion.
    ``(2) Effective upon the expiration of 30 days after the effective 
date of this subsection--
            ``(A) the approved application under subsection (b) or (j) 
        of any drug whose intended use infringes the right to life 
        within the meaning of paragraph (1) is deemed to have been 
        withdrawn under subsection (e) or (j)(6), respectively; and
            ``(B) a drug to which subparagraph (A) applies shall be 
        considered adulterated for purposes of section 301.''.
                                 <all>